DEF: OS Therapies Seeks Stockholder Approval for Potential Issuance of Common Stock Exceeding 20% Threshold

OS Therapies Incorporated is seeking stockholder approval for the potential issuance of common stock exceeding 20% of outstanding shares related to the conversion of preferred stock and exercise of warrants from a recent private placement.

Summary

• OS Therapies Incorporated is holding a Special Meeting of Stockholders on March 31, 2025, to vote on two proposals.
• The first proposal seeks approval for the issuance of common stock upon the conversion of Series A Senior Convertible Preferred Stock and the exercise of warrants, potentially exceeding 20% of the company's outstanding common stock as of December 24, 2024.
• This issuance relates to a private placement that closed in two tranches on December 31, 2024, and January 14, 2025, involving the issuance of 1,775,750 shares of Series A Preferred Stock and warrants.
• The second proposal concerns the adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are insufficient votes to approve the first proposal.
• The Board of Directors recommends voting FOR both proposals.
• The record date for determining stockholders eligible to vote at the Special Meeting was February 12, 2025.
• As of the record date, there were 21,765,302 shares of common stock outstanding.
• If the Issuance Proposal is not approved, the company is required to call a meeting every four months seeking Stockholder Approval until Stockholder Approval is obtained.

Sentiment

Score: 6

Explanation: The document is neutral in tone, primarily focused on procedural matters related to seeking stockholder approval for a previously announced private placement. The potential dilution is a negative, but the capital raise itself is a positive.

Positives

• The private placement has already brought in gross proceeds of approximately $7,103,000.
• The Board of Directors is recommending a vote FOR the Issuance Proposal.

Negatives

• Approval of the Issuance Proposal will have a dilutive effect on existing stockholders, including the voting power and economic rights of the existing stockholders.
• If the Issuance Proposal is not approved, the company is required to call a meeting every four months seeking Stockholder Approval until Stockholder Approval is obtained.

Risks

• Failure to obtain stockholder approval for the Issuance Proposal will require the company to hold additional meetings every four months until approval is secured.
• The anti-dilution and price reset provisions of the Series A Preferred Stock and warrants could result in an increase in the number of shares of common stock issuable upon conversion and exercise in the future.
• The Purchase Agreement restricts the company from issuing additional shares of common stock, or securities convertible into or exercisable or exchangeable for shares of common stock during the period beginning from the closing until the later of (x) six months from the closing and (y) the date Stockholder Approval is obtained and deemed effective, and restricts us from entering into variable rate transactions at any time the Purchasers hold Series A Warrants, subject to certain exceptions.

Future Outlook

The company will be required to call a meeting every four months seeking Stockholder Approval until Stockholder Approval is obtained if the Issuance Proposal is not approved at the Special Meeting.

Management Comments

• Paul A. Romness, MPH, President and Chief Executive Officer, invites stockholders to attend the Special Meeting and encourages them to return their proxy as promptly as possible.

Industry Context

This type of request for stockholder approval is common when companies issue a significant amount of stock or securities convertible into stock, as it can have a dilutive effect on existing shareholders and requires compliance with exchange listing rules.

Comparison to Industry Standards

• The NYSE American LLC Company Guide Section 713(a) requires stockholder approval for transactions involving the sale, issuance, or potential issuance of common stock or securities convertible into common stock, equal to 20% or more of presently outstanding stock for less than the greater of book or market value.
• Many companies listed on exchanges like NYSE American or NASDAQ must seek stockholder approval for issuances exceeding certain thresholds to protect shareholder interests and ensure corporate governance standards are met.
• Similar to OS Therapies, other small-cap biotech companies such as [hypothetical company] and [hypothetical company] have sought stockholder approval for issuances related to financing activities to comply with exchange rules and manage potential dilution.

Related Party Transactions

• Brookline Capital Markets served as the placement agent for the Private Placement and received a cash fee of $159,685 and warrants to purchase 39,918 shares of common stock.
• Ceros Financial Services, Inc., Brookline's selected dealer, received a cash fee of $79,723 and warrants to purchase 19,930 shares of common stock.

Stakeholder Impact

• Approval of the Issuance Proposal will dilute the ownership and voting power of existing stockholders.
• The private placement provides the company with additional capital, which could benefit the company's operations and future prospects.

Next Steps

• Stockholders need to vote on the Issuance Proposal and the Adjournment Proposal before the Special Meeting on March 31, 2025.
• The company will announce preliminary voting results at the Special Meeting and file final results in a Current Report on Form 8-K with the SEC.

Key Dates